Home » FDA Denies Approval for Hemispherx’s Fatigue Drug
FDA Denies Approval for Hemispherx’s Fatigue Drug
Hemispherx Biopharma Inc said U.S. health regulators did not approve its experimental drug Ampligen for the treatment of chronic fatigue syndrome, sending
its shares down 45 percent in after-hours trade.
Forbes
Forbes
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May